256 related articles for article (PubMed ID: 35451727)
1. Contemporary Axillary Management in cT1-2N0 Breast Cancer with One or Two Positive Sentinel Lymph Nodes: Factors Associated with Completion Axillary Lymph Node Dissection Within the National Cancer Database.
Stafford AP; Hoskin TL; Day CN; Sanders SB; Boughey JC
Ann Surg Oncol; 2022 Aug; 29(8):4740-4749. PubMed ID: 35451727
[TBL] [Abstract][Full Text] [Related]
2. Evolution of the Use of Completion Axillary Lymph Node Dissection in Patients with T1/2N0M0 Breast Cancer and Tumour-Involved Sentinel Lymph Nodes Undergoing Mastectomy: A Cohort Study.
Hennigs A; Riedel F; Feißt M; Köpke M; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Heil J
Ann Surg Oncol; 2019 Aug; 26(8):2435-2443. PubMed ID: 31049766
[TBL] [Abstract][Full Text] [Related]
3. Locoregional Management of the Axilla in Mastectomy Patients with One or Two Positive Sentinel Nodes: The Role of Intraoperative Pathology.
Davis J; Boughey JC; Hoskin TL; Day CN; Cheville JC; Piltin MA; Hieken TJ
Clin Breast Cancer; 2021 Oct; 21(5):458-465. PubMed ID: 33839043
[TBL] [Abstract][Full Text] [Related]
4. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
Hennigs A; Köpke M; Feißt M; Riedel F; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Schneeweiss A; Heil J
Breast Cancer Res Treat; 2019 Jan; 173(2):429-438. PubMed ID: 30315437
[TBL] [Abstract][Full Text] [Related]
5. Trends on Axillary Surgery in Nondistant Metastatic Breast Cancer Patients Treated Between 2011 and 2015: A Dutch Population-based Study in the ACOSOG-Z0011 and AMAROS Era.
Poodt IGM; Spronk PER; Vugts G; van Dalen T; Peeters MTFDV; Rots ML; Kuijer A; Nieuwenhuijzen GAP; Schipper RJ
Ann Surg; 2018 Dec; 268(6):1084-1090. PubMed ID: 28742702
[TBL] [Abstract][Full Text] [Related]
6. Inequalities in the omission of axillary dissection in sentinel lymph node positive patients in the Netherlands: Innovative hospitals are early adopters of a de-escalating approach.
van Steenhoven JEC; van Maaren MC; Verreck EEF; Schipper RJ; Nieuwenhuijzen GAP; Kuijer A; Siesling S; van Dalen T
Int J Cancer; 2023 Apr; 152(7):1378-1387. PubMed ID: 36522834
[TBL] [Abstract][Full Text] [Related]
7. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
[TBL] [Abstract][Full Text] [Related]
8. Women Could Avoid Axillary Lymph Node Dissection by Choosing Breast-Conserving Therapy Instead of Mastectomy.
Vane MLG; Hunter-Squires J; Kim S; Smidt ML; Giuliano AE
Ann Surg Oncol; 2021 May; 28(5):2522-2528. PubMed ID: 33586070
[TBL] [Abstract][Full Text] [Related]
9. Omission of axillary lymph node dissection for breast cancer patients with three or more positive sentinel lymph nodes.
Prathibha S; White M; Kolbow M; Hui JYC; Brauer D; Ankeny J; Jensen EH; LaRocca CJ; Marmor S; Tuttle TM
Breast Cancer Res Treat; 2024 May; 205(1):127-133. PubMed ID: 38281296
[TBL] [Abstract][Full Text] [Related]
10. Should patients with hormone receptor-positive, HER2-negative breast cancer and one or two positive sentinel nodes undergo axillary dissection to determine candidacy for adjuvant abemaciclib?
Williams AD; Ruth K; Shaikh SS; Vasigh M; Pronovost MT; Aggon AA; Porpiglia AS; Bleicher RJ
Cancer; 2024 Apr; 130(7):1052-1060. PubMed ID: 38018862
[TBL] [Abstract][Full Text] [Related]
11. Optimizing Axillary Management in Clinical T1-2N0 Mastectomy Patients with Positive Sentinel Lymph Nodes.
Kantor O; Means J; Grossmith S; Dey T; Bellon JR; Mittendorf EA; King TA
Ann Surg Oncol; 2022 Feb; 29(2):972-980. PubMed ID: 34467507
[TBL] [Abstract][Full Text] [Related]
12. Analyzing non-sentinel axillary metastases in patients with T3-T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy.
Riedel F; Heil J; Feisst M; Moderow M; von Au A; Domschke C; Michel L; Schaefgen B; Golatta M; Hennigs A
Breast Cancer Res Treat; 2020 Nov; 184(2):627-636. PubMed ID: 32816190
[TBL] [Abstract][Full Text] [Related]
13. Non-sentinel axillary tumor burden applying the ACOSOG Z0011 eligibility criteria to a large routine cohort.
Riedel F; Heil J; Feißt M; Rezai M; Moderow M; Sohn C; Schütz F; Golatta M; Hennigs A
Breast Cancer Res Treat; 2019 Sep; 177(2):457-467. PubMed ID: 31236814
[TBL] [Abstract][Full Text] [Related]
14. Patterns of completion axillary dissection for patients with cT1-2N0 breast cancer undergoing total mastectomy with positive sentinel lymph nodes.
Schwieger L; Postlewait LM; Subhedar PD; Geng F; Liu Y; Gillespie T; Arciero CA
J Surg Oncol; 2024 Mar; 129(3):468-480. PubMed ID: 37955191
[TBL] [Abstract][Full Text] [Related]
15. De-implementation of Axillary Dissection in Women Undergoing Mastectomy for Breast Cancer.
Leonard LD; de Araujo TB; Quinn C; Thomas MB; Beaty L; Mott NM; Colborn K; Heelan AA; Tevis SEA; Christian N; Arhendt G; Gleisner AL
Ann Surg Oncol; 2023 Sep; 30(9):5692-5702. PubMed ID: 37326811
[TBL] [Abstract][Full Text] [Related]
16. Intraoperative Pathology Assessment May Lead to Overtreatment of the Axilla in Clinically Node-Negative Breast Cancer Patients Undergoing Upfront Mastectomy.
Pride RM; Glass CC; Nakhlis F; Laws A; Weiss AC; Bellon JR; Mittendorf EA; King TA; Kantor O
Ann Surg Oncol; 2023 Oct; 30(10):5978-5987. PubMed ID: 37436607
[TBL] [Abstract][Full Text] [Related]
17. Risk factors of non-sentinel lymph node metastasis in breast cancer with 1-2 sentinel lymph node macrometastases underwent total mastectomy: a case-control study.
Huang Z; Wu Z; Zou QQ; Xie YJ; Li LH; Huang YP; Wu FM; Huang D; Pan YH; Yang JR
World J Surg Oncol; 2023 Apr; 21(1):125. PubMed ID: 37024930
[TBL] [Abstract][Full Text] [Related]
18. Axillary management for young women with breast cancer varies between patients electing breast-conservation therapy or mastectomy.
Tadros AB; Moo TA; Stempel M; Zabor EC; Khan AJ; Morrow M
Breast Cancer Res Treat; 2020 Feb; 180(1):197-205. PubMed ID: 31938938
[TBL] [Abstract][Full Text] [Related]
19. De-escalation of axillary treatment in the event of a positive sentinel lymph node biopsy in cT1-2 N0 breast cancer treated with mastectomy: nationwide registry study (BOOG 2013-07).
de Wild SR; van Roozendaal LM; de Wilt JHW; van Dalen T; van der Hage JA; van Duijnhoven FH; Simons JM; Schipper RJ; de Munck L; van Kuijk SMJ; Boersma LJ; Linn SC; Lobbes MBI; Poortmans PMP; Tjan-Heijnen VCG; van de Vijver KKBT; de Vries J; Westenberg AH; Strobbe LJA; Smidt ML
Br J Surg; 2024 Apr; 111(4):. PubMed ID: 38597154
[TBL] [Abstract][Full Text] [Related]
20. The need to tailor the omission of axillary lymph node dissection to patients with good prognosis and sentinel node micro-metastases.
Houvenaeghel G; de Nonneville A; Chopin N; Classe JM; Mazouni C; Chauvet MP; Reyal F; Tunon de Lara C; Jouve E; Rouzier R; Daraï E; Gimbergues P; Coutant C; Azuar AS; Villet R; Crochet P; Rua S; Bannier M; Cohen M; Boher JM
Cancer Med; 2023 Feb; 12(4):4023-4032. PubMed ID: 36127853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
